Get the Stockscreener App
1.68
0.59%
-0.01
Quince Therapeutics Inc stock is traded at $1.68, with a volume of 61,019.
It is down -0.59% in the last 24 hours and up +10.53% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$1.69
Open:
$1.66
24h Volume:
61,019
Relative Volume:
0.18
Market Cap:
$76.39M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-2.00
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
-9.19%
1M Performance:
+10.53%
6M Performance:
+4.35%
1Y Performance:
+125.87%
1-Day Range:
$1.63
$1.70
1-Week Range:
$1.62
$1.87
52-Week Range:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.68 | 88.12M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Using data tools to time your Quince Therapeutics Inc. exitTrend Following Ideas with Volume Confirmation - Newser
Should you hold or exit Quince Therapeutics Inc. nowAI Intraday Market Movement Prediction Tool - Newser
What Fibonacci levels say about Quince Therapeutics Inc. reboundDaily Swing Candidate Analysis with Chart Patterns - Newser
Can trapped investors hope for a rebound in Quince Therapeutics Inc.Free Buy Alerts With Low Risk Confirmation - Newser
Published on: 2025-08-01 20:05:00 - metal.it
Is Quince Therapeutics Inc. a growth stock or a value stockValue Investing Guidance To Watch Now - jammulinksnews.com
What are analysts’ price targets for Quince Therapeutics Inc. in the next 12 monthsBreakout Stocks Opportunities Backed By Experts - jammulinksnews.com
Is Quince Therapeutics Inc. stock bottoming outDaily Market Momentum and Pressure Analysis - Newser
Using RSI to spot recovery in Quince Therapeutics Inc.Free Short Term Buy List With Stop Protection - Newser
What makes Quince Therapeutics Inc. stock price move sharplyAI Generated Buy/Sell Signal Forecast - Newser
Published on: 2025-07-30 23:00:54 - metal.it
Exit strategy if you’re trapped in Quince Therapeutics Inc.Free Risk Adjusted Technical Entry Plan - Newser
How Quince Therapeutics Inc. stock performs during market volatilityReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Wyckoff Accumulation Phase Possible in Quince Therapeutics Inc.Potential Breakout Stock List Published This Week - metal.it
New Product Launches: Will They Boost Quince Therapeutics Inc. Stock in 2025Safe and Scalable Return Strategy Blueprint - Newser
Sector ETF Data Correlates with Strength in Quince Therapeutics Inc.Intraday Trend Analysis for Fast Gains Released - metal.it
Quince Therapeutics Inc. Recovers — But Is It SustainableConservative Entry for High Return Setup Backed - metal.it
What institutional investors are buying Quince Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
What is Quince Therapeutics Inc. company’s growth strategyCapitalize on fast-growing investment opportunities - jammulinksnews.com
What are the technical indicators suggesting about Quince Therapeutics Inc.Unlock exclusive trading strategies for gains - jammulinksnews.com
What makes Quince Therapeutics Inc. stock price move sharply Free Intraday Trend Analysis for Fast Gains - metal.it
How does Quince Therapeutics Inc. compare to its industry peersFree Stock Movement Tracking - jammulinksnews.com
How Quince Therapeutics Inc. stock performs during market volatility Long Hold Investment Strategy with Growth Focus - Newser
Why is Quince Therapeutics Inc. stock attracting strong analyst attentionInvest smarter with real-time trading alerts - jammulinksnews.com
What catalysts could drive Quince Therapeutics Inc. stock higher in 2025Free Investment Case Studies - jammulinksnews.com
What are the latest earnings results for Quince Therapeutics Inc.Double or triple returns - jammulinksnews.com
Has Quince Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Stock Selection - Newser
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Average Price Target from Analysts - Defense World
Quince Therapeutics (QNCX) Registers 17.34M Shares for Resale - GuruFocus
Quince Therapeutics Seeks to Resell 17.34M Shares, Analysts Predict 300% Upside Potential - AInvest
Quince Therapeutics (QNCX) Plans to Offer 6.67 Million Shares - GuruFocus
Is Quince Therapeutics Inc. a good long term investmentFree Stock Market Knowledge Sharing - PrintWeekIndia
What institutions are buying Quince Therapeutics Inc. stock nowFree Market Dynamics Reports - jammulinksnews.com
Can Quince Therapeutics Inc. stock recover from recent declineConsistent triple returns - jammulinksnews.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):